The combination of EGFR with STAT3 inhibitors has shown improved anti-tumor activity in other pre-clinical models [36]; certainly, data from the current study would support further investigation of combining Dacomitinib with a STAT3 inhibitor for SCCHN. The gene discussed is EGFR; the disease is neoplasm.